Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Novo Nordisk (NVO) stock plunges 44% YoY, hitting a 52-week low as bearish signals pile up. New obesity drug deal fails to excite investors, with Eli Lilly’s rival treatment set to launch first.

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Learn More » Should investors buy Novo Nordisk stock? Here is what to know. Patients can't get enough of Novo Nordisk's GLP-1 agonists, which has created headaches for the company The rampant ...